-

Cindy Henderson Named Veristat Chief Commercial Officer

Instrumental to Veristat’s growth, success, and client satisfaction over the last 15 years

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a scientific-minded global clinical research organization (CRO), announced that Cindy Henderson has been promoted to Chief Commercial Officer (CCO) from Executive Vice President, Strategic Development. As CCO, Cindy will continue to oversee all commercial functions including strategy, proposals and contracts, business development, commercial operations and marketing, in addition to driving business expansion and executing on growth opportunities.

With over 30 years’ experience — 15 with Veristat — Cindy provides the innovative leadership necessary to support the intricate and dynamic requirements of Veristat’s growing global client base. Her ability to lend deep insight into the ideal sequence of events for clinical studies to successfully progress forward has helped clients accelerate their therapies through clinical development to regulatory approval and post-marketing.

"Cindy is held in high regard by both clients and the Veristat team. She has been instrumental in developing our strategic roadmap to address the markets growing need for high value, intellectual services. Cindy has been a key contributor to Veristat's growth and reputation in serving Clients developing novel, life enhancing therapies.” stated Patrick Flanagan, Chief Executive Officer at Veristat. “She brings a unique blend of clinical development, customer centricity and commercial expertise to the role, essential qualities as Veristat operates in a complex and highly regulated clinical environment.”

Throughout her career, Cindy has held a variety of leadership positions within the CRO industry. During her tenure at Veristat since 2007, Cindy has led the operational teams, established a strong commercial organization, supported eight global acquisitions, and created an innovative go-to-market strategy which has solidified Veristat’s position as a premier provider of world-class clinical development and regulatory solutions. Prior to joining Veristat, Cindy served as the Senior Manager of Training, Innovations and Processes at Averion International Corporation (now ICON) and was also a leader in the integration team for several key acquisitions supporting their rapid growth. Prior to Averion, Cindy was Associate Director of Data Management at PAREXEL International Corporation.

“Working at Veristat has been the highlight of my career,” stated Cindy Henderson. “It is humbling to reflect on all we have accomplished over the past 15 years, working as an extension of our sponsors’ teams, and overcoming the challenges that present themselves through the clinical development journey. One of the things I am most proud of is the impact we have had on patients. I have had the opportunity to support bringing over 40 drugs to market, most of which address unmet medical needs. There are still so many things I want to accomplish as we continue our work in making a meaningful difference in the lives of patients around the globe.”

Cindy will continue to work out of Veristat’s Southborough, MA office.

About Veristat

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives.

Contacts

Veristat:
Lauren L. Brennan, V.P. of Marketing
media@veristat.com

Veristat

Details
Headquarters: Southborough, MA
CEO: Patrick Flanagan
Employees: 600+
Organization: PRI

Release Versions

Contacts

Veristat:
Lauren L. Brennan, V.P. of Marketing
media@veristat.com

More News From Veristat

Veristat and AOBiome Therapeutics to Present at Clinical Outsourcing Group on Essential Elements of Effective Partnerships with CROs

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced today that it will participate in the Clinical Outsourcing Group – Bay Area 2025 conference, taking place October 21-22, 2025 at the Hyatt Regency San Francisco Airport, Burlingame, CA. Veristat is speaking with AOBiome Therapeutics, a clinical-stage biotech company focusing on inflammatory conditions, on October 21 at 4:45 p.m. PT and will add...

Cook MyoSite and Veristat Partner in Complex, Phase III, Adaptive Clinical Study of Investigational Cell Therapy for Unmet Need in Women’s Health

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announces its successful partnership with Cook MyoSite to support the DigniFI Study, a two-stage, randomized, controlled Phase III trial comparing the safety and efficacy of iltamiocel with placebo in the treatment of female participants with chronic fecal incontinence (FI) and a history of obstetric anal sphincter injury (OASI). Veristat successfully su...

Veristat Congratulates George Medicines on FDA Approval of WIDAPLIK™

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a leading global clinical research organization (CRO) and consultancy, proudly congratulates George Medicines on the U.S. Food and Drug Administration (FDA) approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a novel single pill combination treatment for hypertension in adults, including as initial treatment, to lower blood pressure. The approval of WIDAPLIK™ marks a significant milestone for George Medicines and the patients who will...
Back to Newsroom